the management of hepatitis C virus (HCV) has been revolutionised by the introduction of direct acting antiviral agents (DAAs). Boceprevir and Telaprevir, first generation HCV protease inhibitors (PIs), are the first commercially available DAAs. Their addition to standard therapy with pegylated interferon (PEG) and ribarvarin (riba) has significantly increased virological cure rates (sustained virological response, SVR) in patients with HCV genotype 1(1-5) This article is protected by copyright. All rights reserved.